^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

TNFRSF19 (TNF Receptor Superfamily Member 19)

i
Other names: TNFRSF19, TNF Receptor Superfamily Member 19, TRADE, TROY, TAJ, Toxicity And JNK Inducer, TAJ-Alpha, Tumor Necrosis Factor Receptor Superfamily Member 19, Tumor Necrosis Factor Receptor Superfamily, Member 19
Associations
Trials
8d
Hsa-miR-99a deficiency contributes to MSI-H colorectal cancer progression by activating the mTOR pathway and inducing Th1/Th2 imbalance. (PubMed, Front Immunol)
mIHC analysis indicated reduced Th1 but increased Th2 and Th17 biomarkers in MSI-H CRC. This study identified key genes and immune microenvironment alterations regulated by hsa-miR-99a in CRC, offering novel insights and potential therapeutic targets for CRC treatment.
Journal • MSi-H Biomarker • MSI-H
|
MSI (Microsatellite instability) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • CD8 (cluster of differentiation 8) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • IGF1 (Insulin-like growth factor 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • SLC8A1 (Solute Carrier Family 8 Member A1) • MIR99A (MicroRNA 99a) • SFRP1 (Secreted frizzled related protein 1) • SDC2 (Syndecan 2) • TNFRSF19 (TNF Receptor Superfamily Member 19) • WNT2 (Wnt Family Member 2)
|
MSI-H/dMMR
24d
Unveiling TNFRSF19: a novel tumor suppressor targeting endoplasmic reticulum stress and LGR5/Wnt/β-catenin in cervical cancer. (PubMed, Hum Cell)
Moreover, the inhibitory effect on cell proliferation mediated by TNFRSF19 was effectively reversed upon the restoration of LGR5 expression. This study demonstrates that TNFRSF19 functions as a novel tumor suppressor in CC by activating ER stress and inhibiting the LGR5/Wnt/β-catenin pathway, highlighting its potential as a therapeutic target for CC treatment.
Journal
|
CTNNB1 (Catenin (cadherin-associated protein), beta 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • LGR5 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 5) • TNFRSF19 (TNF Receptor Superfamily Member 19)
2ms
Identification and validation of paraptosis-related prognostic biomarkers in lung adenocarcinoma: An observational study based on transcriptomics and clinical outcomes. (PubMed, Medicine (Baltimore))
Vorinostat and raloxifene exhibited notable binding affinity for PEBP1. Furthermore, an independent prognostic model for LUAD was developed, enhancing our understanding of high-/low-risk cohorts' functional pathways. Drug prediction results provided valuable insights into potential therapeutic strategies for LUAD, warranting further investigation.
Clinical data • Observational data • Journal
|
TNFRSF9 (TNF Receptor Superfamily Member 9) • CDK3 (Cyclin Dependent Kinase 3) • TNFRSF19 (TNF Receptor Superfamily Member 19)
|
Zolinza (vorinostat) • raloxifene hydrochloride
2ms
Application of interpretable machine learning to analyze DNA methylation sites in the progression from oral Leukoplakia to oral squamous cell carcinoma. (PubMed, Integr Biol (Camb))
These multi-layered analyses provide novel insights into epigenetic mechanisms underlying OL to OSCC progression and highlight candidate biomarkers with strong translational potential. By combining IML based methylation modeling with external and cross-omics validation, this study advances the development of reliable, interpretable biomarkers for precision oral cancer diagnostics and management.
Journal
|
TNFRSF9 (TNF Receptor Superfamily Member 9) • FOXP1 (Forkhead Box P1) • SH3PXD2A (SH3 And PX Domains 2A) • TNFRSF19 (TNF Receptor Superfamily Member 19)
2ms
Recent advances in non-alcoholic steatohepatitis-associated hepatocellular carcinoma: immune cells, metabolic dysregulation, and therapeutic strategies. (PubMed, Front Oncol)
Future directions emphasize novel immune targets (MDSCs, SLAMF1), metabolic reprogramming, and microbiota modulation for precision therapies. Integrating multimodal approaches holds promise for halting NASH-to-HCC progression and improving outcomes.
Review • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • TNFRSF9 (TNF Receptor Superfamily Member 9) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta) • PPARA (Peroxisome Proliferator Activated Receptor Alpha) • TNFRSF19 (TNF Receptor Superfamily Member 19)
4ms
Integration of genetic, proteomic, and transcriptomic data identifies therapeutic targets and prognostic biomarkers in bladder cancer. (PubMed, Transl Androl Urol)
Methylation analyses indicated complex regulation of CTSS and TNFRSF19. WFDC1, RHOC, and GSTM4 exhibit therapeutic potential, while MFGE8, CTSS, TNFRSF19, and IL1RAP predict risk and prognosis, providing insights for precision diagnosis and treatment.
Journal
|
ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CTSS (Cathepsin S) • IL1RAP (Interleukin 1 Receptor Accessory Protein) • CD59 (CD59 Molecule) • TNFRSF19 (TNF Receptor Superfamily Member 19)
5ms
HSC-derived exosomal miR-122-5p inhibits EMT and fibrosis of intrahepatic biliary epithelial cells to alleviate primary biliary cholangitis. (PubMed, Front Immunol)
In vivo results indicated that the degrees of inflammatory infiltration and fibrosis in liver tissues of both PBC patients and model mice were more severe than those of normal controls and were then alleviated with exosomal miR-122-5p treatment. In conclusion, exosomal miR-122-5p alleviates liver pathology in PBC by targeting the TNFRSF19/ASK1/p38 MAPK axis, highlighting its potential as both a diagnostic biomarker and a therapeutic target for PBC.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • MIR122 (MicroRNA 122) • TNFRSF19 (TNF Receptor Superfamily Member 19)
7ms
Circulating proteins and bone mineral density: A Proteome-Wide Mendelian Randomization Study. (PubMed, Curr Med Chem)
This large-scale Proteome-Wide MR study introduced novel targets for BMD and osteoporosis at transcriptional and translational levels, presenting new prospects for drug repurposing and development.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • RSPO3 (R-Spondin 3) • TGFBI (Transforming Growth Factor Beta Induced) • RSPO1 (R-Spondin 1) • TNFRSF19 (TNF Receptor Superfamily Member 19)
8ms
Breakdown of blood-brain barrier, astrocytic endfeet swelling, and abnormal behaviors by blockade of TROY signaling in TROY-Fc transgenic mice. (PubMed, Brain Behav Immun)
Behavioral tests revealed that TROY-Fc Tg mice exhibited a reduction in exploratory motivation and an enhancement of responses to stress. Thus, the signaling mediated by unidentified TROY ligand(s)-TROY interaction may be essential for proper neuronal function through the maintenance of intact BBB.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • TJP1 (Tight Junction Protein 1) • AQP4 (Aquaporin 4) • CLDN5 (Claudin 5) • OCLN (Occludin) • TNFRSF19 (TNF Receptor Superfamily Member 19)
10ms
CircTNFRSF19 Facilitates Triple Negative Breast Cancer Cell Growth by Regulating N6-methyladenosine Modification of B3GNT5: Medical biological image simulation. (PubMed, SLAS Technol)
CRISPR/Cas9 gene editing experiments showed that after CircTNFRSF19 was knocked out, the m6A modification level of B3GNT5 was significantly decreased, and the growth rate of TNBC cells was also significantly slowed down. The application of medical thermal image simulation technology revealed that the metabolic activity of the cells in the CircTNFRSF19 knockout group was reduced, and the temperature change of the cell growth area was significantly different from that in the control group.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • TNFRSF9 (TNF Receptor Superfamily Member 9) • TNFRSF19 (TNF Receptor Superfamily Member 19)
over1year
LncRNA ZFPM2-AS1 promotes phyllodes tumor progression by binding to CDC42 and inhibiting STAT1 activation. (PubMed, Acta Pharm Sin B)
Mechanistically, our findings showed that ZFPM2-AS1 is competitively bound to CDC42, inhibiting ACK1 and STAT1 activation, thereby launching the transcription of TNFRSF19. In conclusion, our study provides evidence that ZFPM2-AS1 plays a pivotal role in the pathogenesis of breast PT, and suggests that ZFPM2-AS1 could serve as a prognostic indicator for patients with PT as well as a promising novel therapeutic target.
Journal
|
TNFRSF9 (TNF Receptor Superfamily Member 9) • STAT1 (Signal Transducer And Activator Of Transcription 1) • TNFRSF19 (TNF Receptor Superfamily Member 19)
almost2years
Cancer-associated fibroblasts (CAFs) gene signatures predict outcomes in breast and prostate tumor patients. (PubMed, J Transl Med)
We identified a huge heterogeneity in the transcriptional profile of CAFs derived from breast and prostate tumors. Of note, the two novel CAFs-related gene signatures might be considered as reliable prognostic indicators and valuable biomarkers for a better management of breast and prostate cancer patients.
Journal • Gene Signature
|
SPP1 (Secreted Phosphoprotein 1) • TNFRSF9 (TNF Receptor Superfamily Member 9) • LIFR (LIF Receptor Subunit Alpha) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2) • CD40LG (CD40 ligand) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • CXCL6 (C-X-C Motif Chemokine Ligand 6) • IL7 (Interleukin 7) • TSLP (Thymic Stromal Lymphopoietin) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • IL33 (Interleukin 33) • ITGA1 (Integrin Subunit Alpha 1) • ITGA2 (Integrin Subunit Alpha 2) • TNFRSF19 (TNF Receptor Superfamily Member 19)